NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News $5.34 +0.30 (+5.95%) (As of 02:32 PM ET) Add Compare Share Share Today's Range$4.99▼$5.4150-Day Range$4.73▼$6.1552-Week Range$2.36▼$6.85Volume114,335 shsAverage Volume206,946 shsMarket Capitalization$240.78 millionP/E RatioN/ADividend YieldN/APrice Target$13.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability ORIC Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside147.2% Upside$13.20 Price TargetShort InterestBearish13.67% of Float Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.20) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector421st out of 1,980 stocksPharmaceutical Preparations Industry181st out of 978 stocks 4.5 Analyst's Opinion Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.20, ORIC Pharmaceuticals has a forecasted upside of 147.2% from its current price of $5.34.Amount of Analyst CoverageORIC Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.67% of the float of ORIC Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 27.5, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 0.94%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreORIC Pharmaceuticals has received a 76.88% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ORIC Pharmaceuticals is -0.58. Previous Next 2.1 News and Social Media Coverage News SentimentORIC Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ORIC Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions82.65% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ORIC Pharmaceuticals (NASDAQ:ORIC) StockORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Stock News HeadlinesMay 31, 2023 | finance.yahoo.comORIC Pharmaceuticals to Participate in the Jefferies Healthcare ConferenceMay 14, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Issued By HC WainwrightJune 1, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 12, 2023 | msn.comHC Wainwright & Co. Maintains ORIC Pharmaceuticals (ORIC) Buy RecommendationMay 11, 2023 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Cut to $14.00 by Analysts at HC WainwrightMay 8, 2023 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.53May 8, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational UpdatesMay 5, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.April 25, 2023 | finance.yahoo.comORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor ConferenceApril 18, 2023 | finance.yahoo.comORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual MeetingApril 6, 2023 | msn.comCitigroup Maintains ORIC Pharmaceuticals (ORIC) Buy RecommendationApril 5, 2023 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) PT Lowered to $8.00 at CitigroupMarch 31, 2023 | finance.yahoo.comOne ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) insider upped their stake by 128% in the previous yearMarch 29, 2023 | finance.yahoo.com‘Charts Point to Higher Highs,’ Says Oppenheimer. Here Are 2 Stocks With Over 100% Upside PotentialMarch 26, 2023 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Lifted to Buy at HC WainwrightMarch 26, 2023 | americanbankingnews.comHC Wainwright Comments on ORIC Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:ORIC)March 23, 2023 | markets.businessinsider.com4 Analysts Have This to Say About ORIC PharmaceuticalsMarch 23, 2023 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.March 22, 2023 | americanbankingnews.comOppenheimer Analysts Boost Earnings Estimates for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)March 21, 2023 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Upgraded by Guggenheim to BuyMarch 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neoleukin Therapeutics (NLTX), RAPT Therapeutics (RAPT) and Oric Pharmaceuticals (ORIC)March 16, 2023 | msn.comOppenheimer Upgrades ORIC Pharmaceuticals (ORIC)March 16, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational UpdatesMarch 16, 2023 | benzinga.comORIC Pharmaceuticals shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $14 price target.March 16, 2023 | finance.yahoo.com6 big analyst picks: Stifel says FedEx stock is a buy | Pro RecapMarch 14, 2023 | finance.yahoo.comORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual MeetingSee More Headlines ORIC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORIC Company Calendar Last Earnings3/16/2023Today6/01/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees78Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.20 High Stock Price Forecast$15.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+161.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.01% Return on Assets-37.02% Debt Debt-to-Equity RatioN/A Current Ratio12.99 Quick Ratio12.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.50 per share Price / Book1.12Miscellaneous Outstanding Shares45,090,000Free Float42,685,000Market Cap$227.25 million OptionableNot Optionable Beta0.49 Key ExecutivesDr. Richard A. Heyman Ph.D. (Age 65)Co-Founder, Independent Chairman & Member of Scientific Advisory Board Comp: $89.92kDr. Jacob M. Chacko M.B.A. (Age 43)M.D., Pres, CEO & Director Comp: $883.68kMr. Dominic G. Piscitelli CPA (Age 47)CPA, M.B.A., Chief Financial Officer Comp: $610.02kDr. Pratik S. Multani M.D. (Age 55)M.S., Chief Medical Officer Comp: $669.76kDr. Charles L. Sawyers B.A. (Age 63)BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Lori Sickels Friedman Ph.D. (Age 58)Chief Scientific Officer Dr. Christian V. Kuhlen Esq. (Age 49)J.D., M.D., Gen. Counsel Mr. Daniel IazzettiVP & Head of PeopleDr. Edna Chow Maneval (Age 62)Sr. VP of Clinical Devel. More ExecutivesKey CompetitorsNkartaNASDAQ:NKTXSpectrum PharmaceuticalsNASDAQ:SPPIVaxxinityNASDAQ:VAXXVerrica PharmaceuticalsNASDAQ:VRCAKamadaNASDAQ:KMDAView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 23,711 shares on 5/16/2023Ownership: 0.682%Jane Street Group LLCBought 173,159 shares on 5/16/2023Ownership: 0.384%Squarepoint Ops LLCBought 37,400 shares on 5/16/2023Ownership: 0.083%Susquehanna International Group LLPSold 14,200 shares on 5/16/2023Ownership: 0.000%Balyasny Asset Management L.P.Bought 11,725 shares on 5/16/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions ORIC Stock - Frequently Asked Questions Should I buy or sell ORIC Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares. View ORIC analyst ratings or view top-rated stocks. What is ORIC Pharmaceuticals' stock price forecast for 2023? 5 Wall Street research analysts have issued 12-month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $13.20 in the next twelve months. This suggests a possible upside of 161.9% from the stock's current price. View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts. How have ORIC shares performed in 2023? ORIC Pharmaceuticals' stock was trading at $5.89 at the beginning of the year. Since then, ORIC stock has decreased by 14.4% and is now trading at $5.04. View the best growth stocks for 2023 here. When is ORIC Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ORIC earnings forecast. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04. What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG). When did ORIC Pharmaceuticals IPO? (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. What is ORIC Pharmaceuticals' stock symbol? ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC." Who are ORIC Pharmaceuticals' major shareholders? ORIC Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (8.89%), Prosight Management LP (3.43%), BlackRock Inc. (1.53%), Renaissance Technologies LLC (0.76%), Geode Capital Management LLC (0.68%) and ArrowMark Colorado Holdings LLC (0.57%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller. View institutional ownership trends. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ORIC Pharmaceuticals' stock price today? One share of ORIC stock can currently be purchased for approximately $5.04. How much money does ORIC Pharmaceuticals make? ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $227.25 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. How can I contact ORIC Pharmaceuticals? ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com. This page (NASDAQ:ORIC) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.